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OBJECTIVES We evaluated the feasibility, safety, and diagnostic accuracy of noninvasive pacemaker stress
echocardiography (PASE) test as a potential alternative to exercise or pharmacologic stress in
patients with suspected or known coronary artery disease (CAD).
BACKGROUND Transesophageal atrial pacing echocardiography is an accurate test for detection of CAD, but
its practical impact has been blunted by semi-invasiveness. In the expanding population of
patients with permanent pacemakers (PMs), a pacing stress test can be administered
noninvasively by external programming of the PM.
METHODS In a prospective, multicenter, international study design, transthoracic stress-pacing echocar-
diography was performed in 46 consecutive patients with a permanent PM (33 men, 13
women; age 66.6  11.1 years) with suspected or known CAD. All patients underwent
noninvasive PM-stress test by external programming (10 beats/min increments up to
ischemia or target heart rate). Coronary angiography was performed in all patients
independently of test results. Significant CAD was defined as 50% visually assessed
diameter reduction in at least one major epicardial coronary artery. All coronary angiograms
were scored by Duke prognostic weight values.
RESULTS Fifteen patients were stimulated in atrial, and the remaining 31 in ventricular mode during
stress. No significant side effects were observed. Echocardiographic images were interpretable
in all patients. The average duration of stress was 8.9  3.5 min. Significant CAD was found
in 27 patients. Sensitivity of PASE for identifying patients with significant CAD was 70%,
specificity was 90%, and accuracy was 78%. When any abnormal wall motion at rest that
remained unchanged at peak stress was regarded as a positive result of PASE, then the
sensitivity, specificity, and accuracy levels for identifying patients with significant CAD were
85%, 84%, and 85%, respectively. Four of the eight patients with a false negative did not reach
the target heart rate. The Duke values had significant correlation with values of wall motion
score index at peak stress (r  0.67) and with peak heart rate (r  0.3).
CONCLUSIONS Noninvasive PASE is a simple, rapid, safe, and diagnostically efficient option for patients with
permanent PM and suspected or known CAD. (J Am Coll Cardiol 2002;40:1305–10)
© 2002 by the American College of Cardiology Foundation
Noninvasive diagnosis of coronary artery disease (CAD) in
patients with permanent pacemakers (PMs) is an extremely
difficult task, because the rhythm induced by right ventric-
ular pacing makes the electrocardiogram (ECG) uninter-
pretable (1,2). Perfusion scintigraphy is also burdened by
low specificity in patients with right ventricular PM (3,4),
possibly for a real impairment in coronary flow reserve due
to alteration of left ventricular mechanical activation and
increase in extramural compressive forces (5). The stress
echocardiography test can be an effective option in these
patients, because wall thickening, differently from wall
motion, is not substantially affected by abnormal electrical
activation (6). In addition, alterations in coronary flow
reserve in the presence of normal epicardial coronary arteries
induce perfusion defect more frequently than wall thicken-
ing abnormalities during stress (7).
Previous studies suggest that functional imaging with
either radionuclide ventriculography associated with intra-
venous (IV) pacing (8) or two-dimensional (2D) echocar-
diography associated with transesophageal atrial pacing
(9,10) are safe and accurate methods for the detection of
CAD. In fact, they have similar diagnostic accuracy to
physical and pharmacologic stress—although their practical
impact is blunted by lower feasibility, suboptimal patient
tolerance (11,12), and relatively long preparation time.
Initial, preliminary experiences suggest that the presence
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of a permanent PM can be exploited to perform a pacing
stress test in a totally noninvasive way by programming the
PM to increasing frequencies (13–15). The aim of this study
was to evaluate the feasibility, safety, and diagnostic accu-
racy of a noninvasive PM-stress echocardiography (PASE)
test as a potential alternative for exercise or pharmacologic
stress echocardiography in patients with known or suspected
CAD.
METHODS
Study patients. The Institute of Clinical Physiology Insti-
tutional Review Board approved the study, and all patients
gave informed consent. The study population consisted of
46 patients with a permanent PM (33 men, 13 women; age
66.6  11.1 years) with suspected or known CAD and
transthoracic echocardiogram adequate to assess resting
regional wall motion (the echocardiogram was considered
adequate if 13 out of the maximum 16 segments were
visualized in at least one projection). Inclusion criteria were:
1) chest pain syndrome, clinically suspected to be ischemic
in origin; 2) a patient scheduled to have coronary angiog-
raphy performed on the basis of the advice of the referring
physician, and independently of pacing stress results; and 3)
presence of a permanent PM. Exclusion criteria were: 1)
dilated cardiomyopathy; 2) severe valvular heart disease; 3)
unstable angina or recent myocardial infarction; and 4)
technically poor baseline echocardiographic examination.
The patients’ characteristics are summarized in Table 1.
PASE protocol. The examination was performed with the
patient in the left lateral decubitus position. Two-
dimensional (2D) echocardiography images were obtained
before echocardiography pacing was begun and every 3 min
thereafter throughout the stress test; the last recording was
obtained 4 min after pacing stress testing. Pacing was
started at the rate of 100 beats/min. Pacing protocol (Fig. 1)
was either “standard” (with a 10-beat increment every 3
min) or “accelerated” (with a 10-beat increment every 60 s)
until one of these criteria was reached: 1) 85% of maximal
heart rate (age-corrected: 220  age for men, 200  age for
women); 2) PM maximal programmable heart rate (which
varied widely, according to the model of PM, up to 170
beats/min during stress); 3) other standard end points.
Patients paced in atrial mode sustaining second-degree
Wenckebach atrioventricular block during pacing were
given IV atropine, 0.4 to 2 mg, as necessary in 0.4-mg
increments every 30 s until 1:1 capture was achieved.
Diagnostic end points of stress testing were target heart rate;
obvious echocardiography positivity; severe chest pain; ob-
vious ECG changes (2 mm ST-segment shift). Submaxi-
mal nondiagnostic end points were: intolerable symptoms;
limiting asymptomatic side effects such as hypertension
(systolic arterial pressure 220 mm Hg, diastolic arterial
pressure 120 mm Hg); hypotension, relative or absolute
(30 mm Hg drop in blood pressure); supraventricular
arrhythmias (supraventricular tachycardia, atrial fibrilla-
tion); and ventricular arrhythmias (ventricular tachycardia,
frequent and polymorphic premature ventricular beats). A
12-lead ECG was recorded at baseline, at peak heart rate,
and immediately after pacing. Left ventricular wall motion
abnormalities were evaluated at rest, during peak pacing,
and immediately after the pacing was stopped.
For segmental wall motion assessment, we used the
16-segment model according to the recommendation of the
American Society of Echocardiography (16) and previously
employed in stress echocardiography multicenter trials
(17,18). In all studies, segment wall motion was graded as 1
 normal; 2  hypokinetic; 3  akinetic; and 4 
dyskinetic. When patients were ventricularly paced, septal
function was evaluated based upon systolic thickening—not
on septal motion, which may be altered by ventricular
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
ECG  electrocardiogram
IV  intravenous
PASE  pacemaker stress echocardiography
PM  pacemaker
2D  two-dimensional
Table 1. Patients’ Characteristics (n  46)
n (%)
Age (yrs) 66.6  11.1
Gender (F/M) 13/33 (28.3%/72.7%)
LVEF 56.2  12.8
Diabetes mellitus 7 (15.2%)
Systemic hypertension 22 (47.8%)
Previous MI 17 (37.0%)
CABG 8 (17.4%)
PTCA 5 (10.9%)
Nitrate treatment 18 (39.1%)
Beta-blocker treatment 16 (34.8%)
Calcium-antagonist treatment 10 (21.7%)
ACE inhibitor treatment 11 (23.9%)
Diuretic treatment 4 (8.7%)
Data are presented as the mean value  SD (%) of patients.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft
surgery; LVEF  left ventricular ejection fraction; MI  myocardial infarction;
PTCA  percutaneous transluminal coronary angioplasty.
Figure 1. “Standard” and “accelerated” pacing protocols.
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pacing. It had been agreed a priori to ignore “mild” or
“questionable” hypokinesia, which was graded as normal.
Segments with baseline abnormalities that did not change in
severity during pacing were evaluated as nonischemic. Ejec-
tion fraction was evaluated with the area-length biplane
method. A test result was considered positive when the wall
motion score increased by one grade or more at peak stress
(for example, a normal segment becoming hypokinetic,
akinetic, or dyskinetic; or a hypokinetic segment becoming
akinetic or dyskinetic); however, an akinesia becoming
dyskinesia was not considered a criterion of positivity.
Adequately visualized segments were scored. Stimulation
was carried on, wherever possible, in atrial stimulation
mode, to have a normal contraction sequence. In the
remaining cases, a ventricular stimulation mode was used.
The feasibility of PASE was evaluated by the following
variables: rapidity, safety, and tolerability. The elapsed time
from the beginning of technical preparations to the end of
the study (including study image interpretation) was re-
corded. Adverse events were assessed (intolerable symp-
toms, ventricular or supraventricular tachycardia, hypoten-
sion, hypertension, atrial fibrillation).
All studies were performed and interpreted in the 10
peripheral centers recruiting the patients by an experienced
cardiologist with documented experience in stress echocar-
diography and who has passed the quality-control proce-
dures of stress echocardiography reading according to cri-
teria adopted in the Echo Persantine International
Cooperative and Echo Dobutamine International Cooper-
ative studies (17,18). The echocardiographers were blinded
to clinical information and angiographic data. Digitized
images and videotape recordings were used for analysis.
Coronary angiography. Angiographic studies were per-
formed and interpreted by experienced observers who had
no knowledge of the PASE test results. All coronary
angiogram reports were sent centrally for qualitative evalu-
ation in the coronary laboratory. A vessel was considered to
have significant obstruction if its diameter was narrowed
50%. From the raw data, a semiquantitative measure of
the extent and severity of CAD was also evaluated by means
of the Duke scoring system (19). This CAD prognostic
index considers the number of the diseased vessels (one-,
two-, and three-vessel, as well as left main disease) and also
involvement of the left anterior descending coronary artery,
particularly when there is involvement of the proximal
segment or the stenosis is severe (i.e., 95% diameter
narrowing). The range of the prognostic weight is a 0 to 100
grade scale (0  no disease; 100  severe disease).
Statistical analysis. Continuous measures are expressed as
the mean value  SD. When appropriate, 95% confidence
intervals (CI) are given. Continuous variables are analyzed
according to the Student t test. Dichotomous variables are
compared by chi-square analysis. Calculations of sensitivity,
specificity, and accuracy were done according to standard
definitions. Standard linear regression analysis was used to
analyze relations between peak heart rate and peak wall
motion score index versus Duke score. A p value of 0.05
was considered significant.
RESULTS
Forty-six consecutive patients (33 men, 13 women; age 66.6
 11.1 years) were studied. In all patients the mean total
duration of the test, including technical preparations and
interpretation of the echocardiographic images, was 37  6
min, with a median time of 32 min (27 to 46 min). The
mean duration of pacing was 8.9  3.5 min, with a median
time of 8 min. Sixteen patients were stimulated in VVI
mode, 12 in DDD, 15 in AAI, and 3 in VDD mode during
stress. The assessment of septal function in the 31 ventricu-
larly paced patients was based upon septal thickening, not
on septal motion. In the 15 patients stimulated in AAI
mode, IV atropine (0.4 to 0.8 mg) was administered in 2
patients sustaining second-degree Wenckebach atrioven-
tricular block during pacing.
Feasibility of PASE. Pacemaker stress echocardiography
was completed in all patients. Echocardiographic images
were interpretable in all patients. No major adverse effects
were observed. One patient had nausea.
Hemodynamic data. Of 46 patients, 42 (91.3%) achieved
at least 85% of their predicted target heart rate or positive
test end point, and 4 patients (8.7%) did not reach the target
heart rate: 2 patients for fixed upper rate response of the PM
and 2 for low Wenckebach point during AAI pacing mode.
During the test, heart rate and rate-pressure product in-
creased significantly (p  0.001), whereas systolic and
diastolic blood pressure did not change significantly. The
hemodynamic changes are presented in Table 2.
Angiographic data. Coronary angiography was performed
in all patients. Significant CAD was found in 27 patients
(59%); among them, one-vessel disease was found in 8
patients (29.6%) and multivessel disease in 19 others
(70.4%). The mean Duke score in patients with CAD was
46.2  16.6.
Stress echocardiographic findings. The PASE was posi-
tive in 26 patients (56.5%) and negative in 20 others
(43.5%). In patients with CAD, wall motion score index
increased from 1.32  0.43 at rest to 1.57  0.47 during
stress test (p  0.001). In patients without CAD, wall
motion score index did not change significantly (1.05 
0.19 vs. 1.11  0.26, p  NS). In 36 of 46 patients the
PASE findings accorded with the findings of coronary
Table 2. Hemodynamic Changes During PASE (n  46)
Base Peak Stress p Value
Heart rate (beats/min) 70.5  8.6 127.1  18.2  0.001
Systolic blood pressure
(mm Hg)
143.8  17.5 145.1  19.6 NS
Diastolic blood pressure
(mm Hg)
82.8  8.8 84.6  11.5 NS
Rate-pressure product
(beats/min  mm Hg/100)
102.0  17.0 184.5  36.2  0.001
NS  nonsignificant; PASE  pacemaker stress echocardiography.
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angiography (78% accuracy, 95% CI  64% to 88%). There
were 19 patients with true positive and 17 patients with true
negative results (70% sensitivity, 95% CI  51% to 84%,
and 89% specificity, 95% CI  68% to 97%) (Fig. 2). Two
patients had false positive PASE and 8 had a false negative
test. The two false positive results occurred in the septum-
apical region in a patient paced in atrial mode, and in the
septo-apical, anterior, and lateral wall in a ventricularly
paced patient. A submaximal test (inability to reach target
heart rate) was found in four of the eight patients with false
negative test. In two of them, a low Wenckebach point was
seen, but no atropine was given (patient did not give consent
to IV drug injection). The peak heart rate was lower in false
negative tests when compared to the 17 true negative tests
(121.3  14.6 vs. 136.9  17.6 beats/min, p  0.05). The
peak rate-pressure product also tended to be lower in false
negative tests when compared to the true negative tests
(176.3  42.3 vs. 194.6  32.1, p  NS). The negative
predictive value of the test was 68% and the positive
predictive value was 90%.
In a cohort of patients with single-vessel disease, sensi-
tivity of the PASE was 38% (95% CI  14% to 70%),
specificity 84% (95% CI  62% to 94%), and accuracy 70%
(95% CI  51% to 84%). In patients with multivessel
disease, sensitivity, specificity, and accuracy were 79% (95%
CI 56% to 91%), 78% (95% CI 59% to 89%), and 78%
(95% CI  64% to 88%), respectively. The diagnostic
accuracy was similar in patients on (n 16) and off (n 30)
beta-blockers (87%, 95% CI  63% to 96% vs. 73%, 95%
CI  55% to 86%, p  NS).
When any abnormal wall motion at rest that remained
unchanged at peak stress was regarded as a positive result of
PASE, the test findings were concordant with the findings
of coronary angiography in 39 of 46 patients (85% accuracy,
95% CI 72% to 92%) (Fig. 2). In 23 patients, results were
true positive (85% sensitivity, 95% CI  67% to 94%), and
in 16 patients the results were true negative (84% specificity,
95% CI  62% to 94%).
The values of the wall motion score index at peak stress
showed a good correlation with severity of coronary lesions
assessed by Duke prognostic weight values (Fig. 3). The
Duke score showed a significant, albeit weak, correlation
with peak heart rate during pacing stress (Fig. 4).
DISCUSSION
The clinical experience of the last 30 years has supported the
efficacy of pacing as a stress test, especially when combined
with imaging techniques such as radionuclide ventriculog-
raphy (8) or 2D echocardiography (9,10,20).
Pathophysiologic mechanism of pacing-induced ischemia.
The pathophysiologic rationale of pacing stress is obvious,
with the stress determined by a controlled increase of heart
rate, which is a major determinant of myocardial oxygen
demand, and thereby tachycardia may exceed a fixed coro-
nary flow reserve in the presence of hemodynamically
significant CAD.
The drop in subendocardial-to-subepicardial flow ratio
associated with rapid pacing in the presence of a tight
coronary stenosis (21) is critical to the development of
regional dysfunction, for regional percent systolic thicken-
ing is linearly and tightly related to subendocardial, not to
transmural, flow (22). In patients with permanent right
ventricular pacing, perfusion defects can often be found in
the inferior and apical wall, which are probably the earliest
activated sites under right ventricular apical pacing (5). The
Figure 2. Diagnostic value of pacemaker stress echocardiography test.
Open bars  new or worsening WMA; solid bars  new, worsening, or
fixed WMA. WMA  wall motion abnormalities. Figure 3. Correlation between wall motion score index (WMSI) at peak
pacing stress and angiographically assessed Duke score.
Figure 4. Correlation between peak heart rate (HR) and angiographically
assessed Duke score.
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regional coronary flow reserve can be impaired in the
dominant coronary artery perfusing these regions, whereas it
is usually normal in the left anterior descending coronary
artery (23). This abnormality is at least partially responsible
for the uncertain specificity of dipyridamole myocardial
perfusion scintigraphy (5) and may have contributed to the
development of one of the two positive results found in our
series involving the apical wall in a VVI-paced patient.
Advantages of PASE. The presence of a permanent PM
can be exploited to perform a pacing stress in a totally
noninvasive way by programming the PM to increasing
frequencies (13–15). In contrast to exercise echocardiogra-
phy, during atrial pacing, echocardiographic images are of
unchanged quality when compared with resting images. It
can also be performed in patients with poor exercise toler-
ance. In patients with PM, we found that PASE is a
feasible, fast, and well-tolerated method. Pacing stress
echocardiography has several advantages in comparison to
conventional diagnostic techniques: The ability to instantly
lower heart rate and to terminate stress result in high test
safety. The short duration of PASE and the possibility to
perform the test at bedside make it very well tolerated by the
patient and user-friendly for the physician. Differently from
physical stress, it does not require patient capability to
exercise; differently from pharmacological stress, it does not
require an IV line and the additional cost (and risk) of drug
administration (24). The PASE requires a shorter prepara-
tion time than does the pharmacologic test; this is because
it does not require the placement of an IV line, unless
atropine is needed. It also has a shorter imaging time,
because the median time of pacing was 8 min, and even less
with the accelerated protocol, which compares favorably with
the 10 min of infusion time for dipyridamole and 20 min
of dobutamine (24). Thus, the PASE has a high potential
usefulness for safe and rapid identification of significant coro-
nary artery stenoses in patients with a PM.
Limitations of PASE. The major obvious pathophysio-
logic limitation is that pacing stress determines only an
increase in heart rate, while systolic blood pressure remains
unchanged. Accordingly, the rate-pressure product in-
creased only moderately, and to a lower extent than during
exercise stress test—as demonstrated (11). As previously
shown, the normal response to tachycardia induced by atrial
pacing was a decrease in ventricular volumes without a
change in ejection fraction or cardiac output (25). This
hemodynamic profile may account for the suboptimal sen-
sitivity of the PASE echocardiography in patients with
single-vessel disease, especially when the target heart rate
cannot be achieved.
From an echocardiographic viewpoint, ventricularly
paced patients have abnormalities in septal motion (6). One
should clearly separate AAI mode from ventricular pacing
mode. In the AAI mode, there is a normal septal contrac-
tion pattern (26), and there are no special interpretation
problems. About two out of three of our patients were
studied in the ventricular pacing mode. In about 30% of
right ventricular-paced patients, the septal wall motion is
normal (26), but in the majority of them an anterior systolic
interventricular septal motion (paradoxal motion) is present
at baseline. In this case the interpreter must focus on wall
thickening rather than endocardial excursion, and on non-
septal regions of the left anterior descending territory to
identify left anterior descending stenosis, but this interpreta-
tion will always be a challenge, especially at high heart rates.
Another obvious limitation of PASE is that it can only be
applied to patients with a permanent PM, which are,
however, a large and expanding population in today’s
cardiology practice (27). The external programming of the
permanent PM is also simple and fast, but it requires
technology (external programmer) and expertise not readily
available in the echocardiography laboratory—with the need
of minimum cooperation and coordination with the pace-
maker laboratory—which is usually, but not always and
anywhere, easy to obtain.
Comparison with earlier studies. We found that PASE
has a diagnostic accuracy of 85%, similar to that observed in
other validation studies of permanent pacing (13–15), trans-
esophageal pacing (9,10), and pharmacologic or exercise
stress echocardiography (11,12). However, differently from
transesophageal pacing, PASE has a markedly higher fea-
sibility with shorter preparation time.
The PASE proved to be effective not only for primary
diagnosis, but also for CAD severity stratification, especially
when peak wall motion score index was estimated. This is
consistent with previous studies with transesophageal atrial
pacing, describing a good correlation between coronary
score and peak pacing wall motion score index (28).
We were able to achieve target heart rate or positive test
end point in 42 patients (91.3%) despite the fact that a
significant number of patients received beta-blockers
(34.8%) and calcium antagonists (21.7%). The main source
of a false negative result was the inability of some type of
PM to reach the target heart rate and/or low Wenckebach
point. The results of the PASE test in some of these
patients is negative, submaximal, and cannot be considered
an adequate form of stress testing.
Study limitations. The gold standard used for comparison
of noninvasive test results was the angiographically assessed
CAD. It is known that angiographic stenosis is not neces-
sarily related to the degree of impairment in regional
coronary flow reserve. Furthermore, the visual assessment
suffers from relatively high intraobserver and interobserver
variability. Although a subjective visual estimate of “percent
stenosis” lacks accuracy and repeatability and does not
provide accurate insight into the hemodynamic impact of a
lesion, the simplicity of the percent stenosis estimate and
the force of tradition favor its continued use: in most
cardiology centers, the visual assessment of coronary steno-
sis remains the definitive gold standard.
A second limitation is inherent in the sensitivity–
specificity approach that we used; this approach requires a
dichotomous response for both test results and CAD when
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all, in fact, show a continuous spectrum of severity. There-
fore, in the present study we also evaluated an integrated
semiquantitative parameter of CAD severity (Duke score)
and of pacing echocardiography response (wall motion score
index, pacing time). The titration of positive response by
PASE was effective in disease-severity stratification.
In our study there was no centralized reading of stress
echocardiogram. Each echocardiogram (either at baseline or
during stress) was interpreted at the peripheral center, and
this reading was directly entered into the data bank. In some
centers only a few studies were performed. Results might
have been affected by interinstitutional variability in read-
ings of stress echocardiograms (29). However, this system
allowed substantial sparing of human and technologic re-
sources. In addition, all centers observed strict quality control
for stress echocardiography reading prior to entering the study.
Furthermore, both the data collection and the data interpre-
tation in the primary care recruiting centers were more likely to
offer a realistic picture of the “effectiveness” of the test—that is,
the real performance of the test in the clinical arena, outside the
“ideal” conditions of an “efficacy” study (30).
Conclusions. Noninvasive PASE is a simple, rapid, safe,
and diagnostically efficient option for patients with perma-
nent PM and suspected or known CAD. Noninvasive
PASE might become the method of choice for diagnostic
assessment of CAD in patients with a permanent PM. The
main source of false negative result is the inability to reach
the target heart rate. The main limitation of the test is the
clearly suboptimal sensitivity in patients with single-vessel
disease.
Reprint requests and correspondence: Dr. Eugenio Picano,
Institute of Clinical Physiology, Via Moruzzi, 1 56126 Pisa, Italy.
E-mail: picano@ifc.cnr.it.
REFERENCES
1. Chaitman BR. Exercise stress testing. In: Braunwald E, editor. Heart
Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadel-
phia, PA: Saunders, 2001:129–55.
2. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for
Exercise Testing. A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
(Committee on Exercise Testing). J Am Coll Cardiol 1997;30:260–311.
3. Lakkis NM, Zuo-Xiang HE, Verani MS. Diagnosis of coronary artery
disease by exercise thallium-201 tomography in patients with a right
ventricular pacemaker. J Am Coll Cardiol 1997;29:1221–5.
4. Tse HF, Lau CP. Long-term effect of right ventricular pacing on
myocardial perfusion and function. J Am Coll Cardiol 1997;29:744–9.
5. Skalidis EI, Kochiadakis GE, Koukouraki SI, et al. Myocardial
perfusion in patients with permanent ventricular pacing and normal
coronary arteries. J Am Coll Cardiol 2001;37:124–9.
6. Gomes JA, Damato AN, Akhtar M, et al. Ventricular septal motion
and left ventricular dimensions during abnormal ventricular activation.
Am J Cardiol 1977;39:641–50.
7. Picano E, Palinkas A, Amyot R. Diagnosis of myocardial ischemia in
hypertensive patients. J Hypertens 2001;19:1177–83.
8. Tzivoni D, Weiss AT, Solomon J, et al. Diagnosis of coronary artery
disease by multigated radionuclide angiography during right atrial
pacing. Chest 1981;80:562–5
9. Chapman PD, Doyle TP, Troup PJ, et al. Stress echocardiography
with transesophageal atrial pacing: preliminary report of a new method
for detection of ischemic wall motion abnormalities. Circulation
1984;70:445–55.
10. Atar S, Nagai T, Cercek B, et al. Pacing stress echocardiography: an
alternative to pharmacologic stress testing. J Am Coll Cardiol 2000;
36:1935–41.
11. Marangelli V, Iliceto S, Piccinni G, De Martino G, Sorgente L,
Rizzon P. Detection of coronary artery disease by digital stress echocar-
diography: comparison of exercise, transesophageal atrial pacing and
dipyridamole echocardiography. J Am Coll Cardiol 1994;24:117–24.
12. Schroder K, Voller H, Dingerkus H, et al. Comparison of the
diagnostic potential of four echocardiographic stress tests shortly after
acute myocardial infarction: submaximal exercise, transesophageal
atrial pacing, dipyridamole, and dobutamine-atropine. Am J Cardiol
1996;77:909–14.
13. Volkov GV, Osipov MA, Bashinskii SE, et al. A new method for the
diagnosis of myocardial ischemia in patients with an implanted
programmable pacemaker. Ter Arkh 1994;66:25–7.
14. Baldo V, Biscione F, Battista M, Baldo E, Lombardi D. Right
ventricular echo-pacing test in the diagnosis of ischemic cardiopathy in
patients with VVI pace-maker. Cardiovasc Imag 1997;8:342–6.
15. Benchimol D, Mazanof M, Dubroca B, et al. Detection of coronary
stenoses by stress echocardiography using a previously implanted
pacemaker for ventricular pacing: preliminary report of a new method.
Clin Cardiol 2000;23:842–8.
16. Armstrong WF, Pellikka PA, Ryan T, et al. Stress echocardiography:
recommendations for performance and interpretation of stress echo-
cardiography. Stress Echocardiography Task Force of the Nomencla-
ture and Standards Committee of the American Society of Echocar-
diography. J Am Soc Echocardiogr 1998;11:97–104.
17. Picano E, Landi P, Bolognese L, et al. A prognostic value of
dipyridamole echocardiography early after uncomplicated myocardial
infarction: a large-scale, multicenter trial. The EPIC Study Group.
Am J Med 1993;95:608–18.
18. Picano E, Mathias W, Pingitore A, et al., on behalf of the EDIC
Study Group. Safety and tolerability of dobutamine-atropine stress
echocardiography: a prospective, large scale, multicenter trial. Lancet
1994;344:1190–2.
19. Smith LR, Harrell FE, Rankin JS, et al. Determinants of early vs. late
death in patients undergoing coronary artery bypass graft surgery.
Circulation 1991;84:245–53.
20. Iliceto S, Sorino M, D’Ambrosio G, et al. Detection of coronary artery
disease by two-dimensional echocardiography and transesophageal
atrial pacing. J Am Coll Cardiol 1985;5:1188–95.
21. Gong G, Ugurbil K, Zhang J. Transmural metabolic heterogeneity at
high cardiac work states. Am J Physiol 1999;277:H236–42.
22. Takeuchi M, Nohtomi Y, Kuroiwa A. Effect of ventricular pacing on
coronary blood flow in patients with normal coronary arteries. Pacing
Clin Electrophysiol 1997;20:2463–9.
23. Kyriakides ZS, Kolettis TM, Popov T, Mesiskli T, Triantafillou K,
Kremastinos DT. Coronary blood flow changes during atrioventricular
sequential pacing with different atrioventricular delays in normal
individuals. J Interv Card Electrophysiol 1998;2:163–9.
24. Picano E. Stress echocardiography: from pathophysiological toy to
diagnostic tool. Point of view. Circulation 1992;85:1604–12.
25. Rozenman Y, Weiss AT, Atlan H, Gotsman MS. Left ventricular
volumes and function during atrial pacing in coronary artery disease: a
radionuclide angiographic study. Am J Cardiol 1984;53:497–502.
26. Stojnic BB, Stojanov PL, Angelkov L, Pavlovic SU, Radjen GS,
Velimirovic DB. Evaluation of asynchronous left ventricular relaxation
by Doppler echocardiography during ventricular pacing with AV
synchrony (VDD): comparison with atrial pacing (AAI). Pacing Clin
Electrophysiol 1996;19:940–4.
27. Bernstein AD, Parsonnet V. Survey of cardiac pacing and defibrillation
in the United States in 1993. Am J Cardiol 1996;78:187–96.
28. Iliceto S, Papa A, D’Ambrosio G, et al. Prediction of the extent of
coronary artery disease with the evaluation of left ventricular wall
motion abnormalities during atrial pacing. A cross-sectional echocar-
diographic study. Int J Cardiol 1987;14:33–45.
29. Hoffman R, Lethen H, Marwick T, et al. Analysis of interinstitutional
observer agreement in interpretation of dobutamine stress echocardio-
grams. J Am Coll Cardiol 1996;27:330–6.
30. Picano E. Stress echocardiography and Ulysses’ syndrome. In: Picano
E, editor. Stress Echocardiography. 4th ed. Heidelberg, Germany:
Springer-Verlag, 2002:297–304.
1310 Picano et al. JACC Vol. 40, No. 7, 2002
Noninvasive PASE October 2, 2002:1305–10
